KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment

Author： Zeitouni Daniel   Pylayeva-Gupta Yuliya   Der Channing J.   Bryant Kirsten L.  

Publisher： MDPI

E-ISSN： 2072-6694|8|4|45-45

ISSN： 2072-6694

Source： Cancers, Vol.8, Iss.4, 2016-04, pp. : 45-45

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer

By Kim Jae-Young   Stewart Paul A.   Borne Adam L.   Fang Bin   Welsh Eric A.   Chen Yian Ann   Eschrich Steven A.   Koomen John M.   Haura Eric B.  

Proteomes, Vol. 4, Iss. 2, 2016-04 ,pp. : 16-16

MDPI

Access to resources Recommend Favorite

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer

By Deeb Dorrah   Gao Xiaohua   Arbab Ali S.   Barton Kenneth   Dulchavsky Scott A.   Gautam Subhash C.  

Cancers, Vol. 2, Iss. 4, 2010-10 ,pp. : 1779-1793

MDPI

Access to resources Recommend Favorite

Current Surgical Aspects of Palliative Treatment for Unresectable Pancreatic Cancer

By Karapanos Konstantinos   Nomikos Iakovos N.  

Cancers, Vol. 3, Iss. 1, 2011-02 ,pp. : 636-651

MDPI

Access to resources Recommend Favorite

Treatment of Pancreatic Cancer: What Can We Really Predict Today?

By Bachet Jean-Baptiste   Marechal Raphael   Van Laethem Jean-Luc  

Cancers, Vol. 3, Iss. 1, 2011-02 ,pp. : 675-699

MDPI

Access to resources Recommend Favorite

Possible Role of Autophagy in the Treatment of Pancreatic Cancer with Histone Deacetylase Inhibitors

By Rikiishi Hidemi  

Cancers, Vol. 2, Iss. 4, 2010-11 ,pp. : 2026-2043

MDPI

Access to resources Recommend Favorite